256 related articles for article (PubMed ID: 27100432)
1. Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.
Steenholdt C; Coskun M; Buhl S; Bendtzen K; Ainsworth MA; Brynskov J; Nielsen OH
Medicine (Baltimore); 2016 Apr; 95(16):e3417. PubMed ID: 27100432
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
3. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
4. Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-α inhibitor in Crohn disease patients.
Shi X; Yang W; Wang N; Zhu J
Medicine (Baltimore); 2019 Aug; 98(33):e16622. PubMed ID: 31415355
[TBL] [Abstract][Full Text] [Related]
5. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
6. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
[TBL] [Abstract][Full Text] [Related]
7. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.
Minar P; Saeed SA; Afreen M; Kim MO; Denson LA
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):715-22. PubMed ID: 26551317
[TBL] [Abstract][Full Text] [Related]
8. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
[TBL] [Abstract][Full Text] [Related]
9. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
10. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
[TBL] [Abstract][Full Text] [Related]
11. Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
Mateos B; Sáez-González E; Moret I; Hervás D; Iborra M; Cerrillo E; Tortosa L; Nos P; Beltrán B
Dig Dis; 2021; 39(1):1-9. PubMed ID: 32325460
[TBL] [Abstract][Full Text] [Related]
12. Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis.
Takeshita M; Suzuki K; Kikuchi J; Izumi K; Kurasawa T; Yoshimoto K; Amano K; Takeuchi T
Cytokine; 2015 Oct; 75(2):222-7. PubMed ID: 26095743
[TBL] [Abstract][Full Text] [Related]
13. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
14. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.
Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
Eur J Pharm Sci; 2020 Jul; 150():105317. PubMed ID: 32205229
[TBL] [Abstract][Full Text] [Related]
15. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
Tang S; Xiao H; Fan Y; Wu F; Zhang Z; Li H; Yang Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
[TBL] [Abstract][Full Text] [Related]
18. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
Kevans D; Murthy S; Mould DR; Silverberg MS
J Crohns Colitis; 2018 May; 12(6):662-669. PubMed ID: 29659758
[TBL] [Abstract][Full Text] [Related]
19. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
Buhl S; Dorn-Rasmussen M; Brynskov J; Ainsworth MA; Bendtzen K; Klausen PH; Bolstad N; Warren DJ; Steenholdt C
Scand J Gastroenterol; 2020 Aug; 55(8):884-890. PubMed ID: 32631131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
